Is cobenfy safe?

DX'd - Other
1

Is cobenfy safe? I’m sorta worried about it. I see my psych in a few days.

But I think I want to try it.

I am on 3 antipsychotics rn and I don’t want TD from Haldol.

I think cobenfy might be the answer for me if it’s safe. I hope it works wonders.

1 Like
2

Is it even out yet?

3

It’s supposed to be available starting sometime in October, I hope karXT is worth the hype.

1 Like
4

My understanding is it will be extremely expensive. I even heard $1200/month

1 Like
5

Does anyone know if this is an add on AP or a stand alone drug?
I may give it a shot
@everhopeful

6

I just looked it up. It’s listed at $1850 per month! That’s impossible to afford

1 Like
7

cobenfy is approved as monotherapy.

It’s not approved to be used with another AP.

1 Like
8

Ok thanks @everhopeful

1 Like
9

My Mom and pdoc want me to try it but Im doing fine on invega just want to lower the dose

10

@Ribbit If you do try it please let us know what your experience is on it.

11

Will do! @Vinegar

1 Like
12

I read they are doing trials for it as an add on to a second antipsychotic treatment too. I think the trial is called ARISE.

It’s not FDA approved for add on yet but they are studying it from what I understand @everhopeful @Vertigo

Here is what I read (it says I’m new and can’t put the link. It can be found on Clinical Trials Arena website):

“Cobenfy is also being developed as an adjunctive therapy in patients who have an inadequate response to atypical antipsychotic monotherapy. The ongoing Phase III ARISE trial is a six-week, randomised, double-blind, placebo-controlled, multicentre, outpatient study in patients with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. At present, although physicians will occasionally prescribe a second antipsychotic or antidepressant off-label to augment the effects of an antipsychotic, there are no approved combination therapeutic regimens for schizophrenia. Furthermore, KOLs reported only modest improvements in efficacy and increased side-effect burden with this type of polypharmacy. If positive results are found in the ongoing ARISE trial, Cobenfy could be the first approved adjunctive therapy for the treatment of schizophrenia.”

2 Likes